Published in Anti-Infectives Week, December 24th, 2007
"In the model of combination chemotherapy, the interactions between epirubicin and certain resistance modifiers were studied in vitro. Compound 8 proved to be the most active, exhibiting a synergistic interaction. The capacity of the most effective derivative...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Anti-Infectives Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.